Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 4/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 4/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14814725 | 0.91 | LIPE (0.37) | LIPESCN9A | |
| SCHEMBL14814992 | 0.90 | LIPE (0.37) | LIPESCN9ALRRK2PANK3 | |
| SCHEMBL14815029 | 0.90 | PANK3 (0.39) | LIPEKCNH2OPRK1MGLLPANK3 | |
| SCHEMBL14815372 | 0.89 | KCNJ1 (0.36) | LIPEKCNH2S1PR1PANK3 | |
| SCHEMBL14814957 | 0.87 | LIPE (0.45) | LIPEOPRK1SCN9ACNR1 | |
| SCHEMBL14815079 | 0.86 | MEN1 (0.46) | LIPECCR2KCNH2OPRK1SCN9A | |
| SCHEMBL14815116 | 0.85 | MGLL (0.42) | LIPEMGLL | |
| SCHEMBL14814708 | 0.84 | SMN1; SMN2 (0.42) | LIPE | |
| SCHEMBL14814942 | 0.83 | LIPE (0.43) | LIPEMGLL | |
| SCHEMBL14815230 | 0.83 | LIPE (0.41) | LIPEKCNH2MGLLSCN9ACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8669255-B2 | Substituted octahydropyrrolo[1,2-a]pyrazines as calcium channel blockers | ABBVIE INC. (US) | 2014-03-11 | — | — | US | claimed |
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | US | claimed |
| US-8669255-B2 | Substituted octahydropyrrolo[1,2-a]pyrazines as calcium channel blockers | ABBVIE INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | US | disclosed |
| WO-2013049164-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1E, CACNA1D | LIPE 4720/4885EPHX2 2168/4885CCR2 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.